Infinity Pharmaceuticals Cultura de la Empresa

Dr. Lawrence E. Bloch, also known as Larry, M.D., J.D., has been the President of Infinity Pharmaceuticals, Inc. since January 4, 2017 and has been its Principal Accounting Officer since July 25, 2016 and serves as its Treasurer. Dr. Bloch served the Chief Financial Officer, Chief Business Officer and Executive Vice President at Infinity Pharmaceuticals, Inc. since July 24, 2012 until Dec, 2016. Dr. Bloch is responsible for the Infinity Pharmaceuticals's corporate, financial and business development strategies and operations. Dr. Bloch served as Treasurer at Infinity Pharmaceuticals, Inc. Dr. Bloch served as the Chief Executive Officer of NeurAxon Inc. since July 2007 to 2011 and served as its President. Dr. Bloch served as the Chief Financial Officer and Chief Business Officer at NitroMed Inc., from September 13, 2004 to March 21, 2006 and Secretary and Treasurer from November 2004 to March 21, 2006. He served as Secretary at Infinity Pharmaceuticals, Inc. Dr. Bloch had been responsible for overseeing NitroMed's strategic and financial planning, identifying and implementing growth strategies and guiding its relationships with the government and investor communities. He served as Principal Accounting Officer of Applied Molecular Evolution Inc. He served as the Chief Financial Officer and Secretary of Applied Molecular Evolution from March/April 2000 until its merger with Eli Lilly and Company (Lilly) in 2004 and Vice President of Business Development from 1999 to 2002. From 1998 to 1999, he served as a Consultant to several private biotechnology companies, including Applied Molecular Evolution Inc. In 1995, Dr. Bloch co-founded CareCom, Inc. and served as its President from 1995 to 1999. During Dr. Bloch's tenure at AME company and its subsidiary, Novasite Pharmaceuticals, completed multiple private placements, an IPO and ultimately its merger with Lilly. Dr. Bloch serves as a Director of Novasite Pharmaceuticals, Inc. Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Woman's Hospital. He served as a Director of NeurAxon Inc. since July 2007. Dr. Bloch holds a B.S. from Stanford University, a M.Phil in Finance from Cambridge University. Dr. Bloch received a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

Mr. Seth A. Tasker has been Vice President and Secretary at Infinity Pharmaceuticals, Inc. Since July 2016. Mr. Tasker holds responsibility for all aspects of Infinity's legal affairs as well the company's human resources and information technology functions. Mr. Tasker has more than 15 years of experience in the pharmaceutical industry and has expertise in corporate finance and partnering transactions, corporate governance, securities, compliance, employment law and other legal and operational issues relevant to developing new medicines in both the private and public company setting. Prior to joining Infinity, Mr. Tasker served as an Associate Counsel at Surface Logix, Inc. Mr. Tasker received a J.D. and M.B.A from Suffolk University and a B.S. in microbiology from the University of Vermont.

Ms. Melissa Hackel has been Vice President of Finance at Infinity Pharmaceuticals, Inc. January 4, 2017. Ms. Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decision-making. Prior to joining Infinity, Ms. Hackel served as Director of Finance at Takeda Pharmaceutical Company. She received an MBA from Duke University and a B.A. in Political Science from Bates College.

Dr. Jeffery L. Kutok, also known as Jeff, M.D., Ph.D. has been Chief Scientific Officer and Senior Vice President at Infinity Pharmaceuticals, Inc. since February 13, 2017. Dr. Kutok is responsible for overseeing biology and translational science efforts, including preclinical collaborations, to support the ongoing clinical development of IPI-549, Infinity's oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Dr. Kutok joined Infinity in 2010 and was promoted to Vice President, biology and translational science in 2013. Additionally, he has experience in translational research and is a Medical Pathologist.He has made significant contributions to Infinity throughout his tenure, including leading the Infinity team that co-authored two recent Nature publications summarizing preclinical data for IPI-549. Prior to joining Infinity in 2010, Dr. Kutok was an Associate Professor of Pathology at Harvard Medical School and Brigham and Women's Hospital. His laboratory focused on translational medicine research and biomarker identification in cancer and he is an Author on over 190 journal articles, reviews and book chapters. Dr. Kutok is board certified in Anatomic Pathology and Hematology and had clinical duties in Hematopathology and Molecular Diagnostics at Brigham and Women's Hospital. Dr. Kutok received his B.S. in biology and his M.D., Ph.D. in medicine and molecular pathology from the State University of New York at Stony Brook. His Ph.D. was earned working in the laboratory of Dr. Barry Coller, M.D. in the field of platelet pathobiology. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Gary Gilliland, M.D., Ph.D.

Ariane Marolewski serves as the Sr. Director, Analytical for Infinity Pharmaceuticals. Ariane started at Infinity Pharmaceuticals in October of 2013. Ariane is based in the Greater Boston Area.

Mike Foley serves as the VP Chemistry for Infinity Pharmaceuticals Inc.. Mike started at Infinity Pharmaceuticals Inc. in December of . Mike is based in the Greater Boston Area.

Jennifer Johnson serves as the VP for IPI. Jennifer started at IPI in December of . Jennifer is based in the Phoenix, Arizona Area.